Protein could bring hope to brittle bone disease

osteoporotic_bone,_sem-spl

A discovery in mice could help to treat people with a form of brittle bone disease, scientists said.

In an American study, mice were bred with osteogenesis imperfecta (OI) and the activity of a protein which shapes and reshapes bones was monitored. Scientists said intense activity of the protein in the mice was linked to OI.

They said the finding could lead to a new target for treatment, but experts warn the study is in mice and might not apply to humans.

Human trials?
One in 15,000 people in the UK are estimated to have osteogenesis imperfecta (OI). It is an inherited condition, where abnormalities in the genes controlling collagen affect the bone’s strength.

In severe cases, people with OI can have between 200 and 300 fractures by the time they reach age 18, the Brittle Bone Society said. Current treatment is lacking.

Scientists at the Baylor College of Medicine, University of Texas, looked at a protein in mice bred with the condition and compared them to “normal” mice.

They said the activity of transforming growth factor beta (TGF), which co-ordinates the shaping and reshaping of bone, was excessive in mice with OI.

When TGF was blocked with an antibody, the mice’s bones withstood “higher maximum load and ultimate strength” and showed “improved whole bone and tissue strength”, suggesting “resistance to fracture”, the study said.

Research was published in the journal Nature Medicine.

Dr Brendan Lee, professor of molecular and human genetics at Baylor College of Medicine, said the study could “move quite quickly” into humans, and be at a clinical trial stage later this year, or early next year.

‘Open doors’
A pharmaceutical company in the US was looking at the pathway of TGF in other diseases, such as kidney disease, which could accelerate the trials, he said. One mechanism behind the findings could be that the disruption of TGF meant the bone was absorbed in the body more quickly than it was made.

Dr Lee added: “We now have a deeper understanding for how genetic mutations that affect collagen and collagen processing enzymes cause weak bones.”

He said the treatment appeared “even more effective” than other existing approaches.

Prof Nick Bishop, is professor at the University of Sheffield and chairman of the Brittle Bone Society’s medical advisory board. He said the study was a “paradigm shifter” as it exposed a possible new target for treatment.

But Prof Bishop said: “This is another mouse study with potential to transfer to humans, we hope, but remember mice are not human.”

He added: “Other treatments that have worked really well in mice with brittle bones, like bone marrow transplantation, haven’t worked as well in humans and are not standard practice as of now.”

Dr Claire Bowring, medical policy manager at the National Osteoporosis Society, said the study was “basic science” in mouse models to understand the “basics of bone biology”.

She said: “It could, in the future, help develop knowledge about bone conditions more fully. As we understand more about bone turnover and communication between bone cells, work could open doors for future research that could affect osteoporosis.”

Dr Bowring said it could take 10 to 15 years for such mouse studies to reach the stage of clinical trials in people.

Source: BBC


New Tool to Measure the Speed of Aging: Your handshake

ageing

Strong handshake can say a lot about a person — it can indicate power, confidence, health or aggression. Now scientists at Stony Brook University and the Institute for Applied Systems Analysis (IIASA) say that the strength of a person’s grasp may also be one of the most useful ways to measure people’s true age.

In a new study published today in the journal PLOS ONE, IIASA researchers Warren Sanderson, Professor of Economics with joint appointment in History at Stony Brook and Serguei Scherbov show that hand grip corresponds to other markers of aging such as people’s future mortality, disability, cognitive decline and ability to recover from hospital stays.
For their new research, Sanderson and Scherbov reviewed findings from over 50 published studies that focus on people around the world and of all ages. Since the measure is already commonly used, data is readily available.

“Hand-grip strength is easily measured and data on hand-grip strength now can be found in many of the most important surveys on aging worldwide,” says Sanderson.

The study also demonstrates how such a test could be used as a measure for aging to compare different population groups. The study used data from one such survey, the United States Health and Retirement Survey (HRS), to show how this could be done.

Scherbov says, “We found that based on this survey, a 65-year-old white women who had not completed secondary education has the same handgrip strength as a 69-year-old white women who had completed secondary education. This suggests that according to a handgrip strength characteristic their ages are equivalent and 65 year-old women ages 4 years faster due to lower education attainment.”

In a growing body of research funded in part by a new grant from the European Research Council (ERC), Sanderson and Scherbov have begun to define new measures of aging based on people’s characteristics, such as their longevity, health, disability status and other important demographic factors.

Previous research by Sanderson and Scherbov has shown that measuring age simply by the number of years people have lived does not measure variations in the aging process correctly. Using new characteristic-based approaches such as the one in this paper, the researchers can identify differences in the aging process between population groups that may not otherwise become apparent.

Scherbov says, “Our goal is to measure how fast different groups in a society age. If some group is getting older faster than another, we can ask why that might be and see whether there are any policies that could help the faster aging group.”

Source: Science daily


New cure found for HIV virus?

hıv-virüsü

Scientists have discovered new vulnerable site on the HIV virus that can be attacked by human antibodies in a way that neutralizes the infectivity of a wide variety of HIV strains.

The researchers from Scripps Research Institute Scientists working with the International AIDS Vaccine Initiative said that an effective vaccine would work by eliciting a strong and long-lasting immune response against vulnerable conserved sites on the virus-sites that don’t vary much from strain to strain, and that, when grabbed by an antibody, leave the virus unable to infect cells.

Dennis R. Burton, professor in TSRI’s Department of Immunology and Microbial Science, said that HIV has very few known sites of vulnerability, but in this work we’ve described a new one, and we expect it will be useful in developing a vaccine.

The study was published in the journal Immunity.

Source: Yahoo news


Eco-Friendly Diapers Made From Jellyfish

Eco-Friendly Diapers Made From Jellyfish

Move over Brawny, there’s a new product in the works with the strength to get the job done, and it comes from the sea. Cine’al Ltd., an Israeli nanotechnology start-up, is developing a line of super-absorbing products made from jellyfish.

Jellyfish populations worldwide have been exploding in recent years, and the creatures are expected to be one of the few winners of the warming oceans brought about by climate change. They present a real problem: In 2013, a cluster of jellyfish temporarily shut down a nuclear reactor in Sweden after they were sucked into a cooling pipe. However, until now, very few useful purposes have been found for jellyfish.

Enter a second conundrum: Absorbent products such as diapers, medical sponges and feminine pads contain synthetic super-absorbing polymers that take hundreds of years to break down in landfills. These same products made with jellyfish biodegrade in less than 30 days, and they soak up twice the mess, the Times of Israel reports.

A Double Scourge

Cine’al’s product was inspired by research conducted at Tel Aviv University, which harnessed jellyfishes’ ability to absorb high volumes of liquid without deteriorating. By breaking down jellyfish flesh and adding nanoparticles (for antibacterial properties), researchers created a material they call Hydromash, which can be used as an absorbent material in diapers, toilet paper, medical sponges and tampons.

In the United States, a 1998 study from the Environmental Protection Agency found that 3.4 million tons of diapers entered landfills in that year alone. Cine’al’s president Ofer Du-Nour is thus hoping his product will kill two birds with one stone.

“There are too many jellyfish in the sea, and too many Pampers in landfills. Cine’al may have the ultimate answer to both those issues,” Du-Nour told

It’s unclear when, or if, these jellyfish products might arrive in the aisles of supermarkets. According to Green Prophet, Cine’al is currently discussing building manufacturing plants in Korea and South Carolina — where jellyfish fishing operations are already going strong.

Source; Discover


Scientists discover exact mechanism for how broccoli and crucifers fight cancers

broccoli

Researchers fed a special cultivar of broccoli, a combination of wild and commercially available broccoli that contains high levels of glucoraphanin, to nineteen volunteers each week for three months. They compared the first group to two other groups eating the same diet, except one consumed commercially available broccoli and the third ate none of the crucifer. The team observed that those eating the glucoraphanin-rich vegetable showed signs of an improved metabolism.

The scientists determined that a compound commonly found in crucifers, known as sulforaphane, improved the chemical reactions inside mitochondria, the power source for our cellular machinery. The study found that glucoraphanin helped ‘retune’ metabolic processes in the cells that get disrupted as we age. Lead author, Dr. Richard Mithen commented, “We think this provides some evidence as to why people who eat diets rich in broccoli may keep in good health… mitochondria are really, really important, and when they start to go wrong it leads to many of the diseases of aging.”

The nutritionists performing the study recommend eating broccoli two to three times a week. Other health-promoting members of the cruciferous vegetable family include Brussels sprouts, kale and cauliflower. Dr. Mithen concluded “We think it is significant because it shows in humans a measurable effect on our metabolism, which is central to our overall health and could explain the diverse range of beneficial effects many observational dietary studies have shown previously.” It is important to note that while this study used a specially concentrated type of broccoli to produce the stated results, consumption of commercially available broccoli and crucifers have been shown to exhibit similar anti-cancer properties when eaten over a longer period of time

Source: Natural news


Gene Therapy May Boost Cochlear Implants

cochlear-implant

Australian researchers are trying a novel way to boost the power of cochlear implants: They used the technology to beam gene therapy into the ears of deaf animals and found the combination improved hearing.

The approach reported Wednesday isn’t ready for human testing, but it’s part of growing research into ways to let users of cochlear implants experience richer, more normal sound.

Normally, microscopic hair cells in a part of the inner ear called the cochlea detect vibrations and convert them to electrical impulses that the brain recognizes as sound. Hearing loss typically occurs as those hair cells are lost, whether from aging, exposure to loud noises or other factors.

Cochlear implants substitute for the missing hair cells, sending electrical impulses to directly activate auditory nerves in the brain. They’ve been implanted in more than 300,000 people. While highly successful, they don’t restore hearing to normal, missing out on musical tone, for instance.

The idea behind the project: Perhaps a closer connection between the implant and the auditory nerves would improve hearing. Those nerves’ bush-like endings can regrow if exposed to nerve-nourishing proteins called neurotrophins. Usually, the hair cells would provide those.

Researchers at Australia’s University of New South Wales figured out a new way to deliver one of those growth factors.

They injected a growth factor-producing gene into the ears of deafened guinea pigs, animals commonly used as a model for human hearing. Then they adapted an electrode from a cochlear implant to beam in a few stronger-than-normal electrical pulses.

That made the membranes of nearby cells temporarily permeable, so the gene could slip inside. Those cells began producing the growth factor, which in turn stimulated regrowth of the nerve fibers — closing some of the space between the nerves and the cochlear implant, the team reported in the journal Science Translational Medicine.

The animals still needed a cochlear implant to detect sound — but those given the gene therapy had twice the improvement, they concluded.

Senior author Gary Housley estimated small studies in people could begin in two or three years.

“That’s a really clever way” of delivering the nerve booster, said Stanford University otolaryngology professor Stefan Heller, who wasn’t involved with the Australian work. “This is a promising approach.”

But Heller cautioned that it’s an early first step, and it’s not clear how long the extra improvement would last or if it really would spur richer sound. He said other groups are exploring such approaches as drug coatings for implants; Heller’s own research is aimed at regrowing hair cells.

Source: abc news


Bionic eye allows Michigan man to see glimpses

bionic-eye

A few people who have lost their sight due to a rare disorder are regaining some vision thanks to a high-tech procedure that involved the surgical implantation of a “bionic eye.”

A degenerative eye disease slowly robbed Roger Pontz of his vision. Diagnosed with retinitis pigmentosa as a teenager, Pontz has been almost completely blind for years. Now, thanks to an implant, he’s regained enough of his eyesight to catch small glimpses of his wife, grandson and cat.

“It’s awesome. It’s exciting — seeing something new every day,” Pontz said during a recent appointment at the University of Michigan Kellogg Eye Center. The 55-year-old former competitive weightlifter and factory worker is one of four people in the U.S. to receive an artificial retina since the U.S. Food and Drug Administration signed off on its use last year.

The facility in Ann Arbor has been the site of all four such surgeries since FDA approval. A fifth is scheduled for next month. No retinal prosthesis has been approved for use in Canada, according to the Foundation Fighting Blindness’s website.

Retinitis pigmentosa is an inherited disease that causes slow but progressive vision loss due to a gradual loss of the light-sensitive retinal cells called rods and cones. Patients experience loss of side vision and night vision, then central vision, which can result in near blindness.

Not all of the 100,000 or so people in the U.S. with retinitis pigmentosa can benefit from the bionic eye. An estimated 10,000 have vision low enough, said Dr. Brian Mech, an executive with Second Sight Medical Products Inc., the Sylmar, Calif.-based company that makes the device. Of those, about 7,500 are eligible for the surgery.

The artificial implant in Pontz’s left eye is part of a system developed by Second Sight that includes a small video camera and transmitter housed in a pair of glasses.

Images from the camera are converted into a series of electrical pulses that are transmitted wirelessly to an array of electrodes on the surface of the retina. The pulses stimulate the retina’s remaining healthy cells, causing them to relay the signal to the optic nerve.

The visual information then moves to the brain, where it is translated into patterns of light that can be recognized and interpreted, allowing the patient to regain some visual function.

When wearing the glasses, which Pontz refers to as his “eyes,” he can identify and grab his cat and figure out that a flash of light is his grandson hightailing it to the kitchen.

‘What’s it worth to see again? It’s worth everything’

The visual improvement is sometimes startling for Pontz and his wife, Terri, who is just as amazed at her husband’s progress as he is. “I said something I never thought I’d say: ‘Stop staring at me while I’m eating,”‘ Terri Pontz said.

She drives her husband the nearly 200 miles from tiny Reed City, Mich., to Ann Arbor for check-ups and visits with occupational therapist Ashley Howson, who helps Roger Pontz reawaken his visual memory and learn techniques needed to make the most of his new vision.

At the recent visit, Howson handed Pontz white and black plates, instructed him to move them back and forth in front of light and dark backgrounds and asked that he determine their colour.

Back home, Terri Pontz helps her husband practice the techniques he learns in Ann Arbor.  For them, the long hours on the road and the homework assignments are a blessing. “What’s it worth to see again? It’s worth everything,” Terri Pontz said.

The artificial retina procedure has been performed several-dozen times over the past few years in Europe, and the expectation is that it will find similar success in the U.S., where the University of Michigan is one of 12 centres accepting consultations for patients.

Candidates for the retinal prosthesis must be 25 or older with end-stage retinitis pigmentosa that has progressed to the point of having “bare light” or no light perception in both eyes.

Dr. Thiran Jayasundera, one of two physicians who performed the 4.5-hour surgery on Roger Pontz, is scheduled to discuss his experiences with the retinal prosthesis process during a meeting of the American Society of Cataract and Refractive Surgery on Friday in Boston. He calls it a “game-changer.”

Pontz agrees: “I can walk through the house with ease. If that’s all I get out of this, it’d be great.”

Source: CBC news


New blood test could predict arthritis and allow treatment

blood-test-can-predict-who-suffers-arthritis-be-available-5-yrs

A new blood test could predict who will suffer from arthritis before it hits, allowing for early treatment to stop irreparable damage being done. British scientists hope the test could be available within five years – signifying hope for sufferers and potentially saving the NHS millions in expensive joint replacements.

Teams from Bristol University have identified two biomarkers – or indicators in the blood – which could help distinguish between a healthy person and one with osteoarthritis, a move which they hope would then help them identify which patients’ condition will worsen.

A major cause of pain and disability, it’s caused by wear and tear on the joints, specifically the cartilage. It also leads to the synovial fluid, a jelly-like substance which is secreted by the membrane that surrounds the joint, becoming thin and less elastic.

The condition occurs more frequently in women than men, can sometimes be very painful, making movement and everyday tasks difficult.

Researcher Dr Mohammed Sharif of Bristol University told the Express that there was an urgent need to find better indicators of the disease, and that he and his team had identified two which were ‘very useful’. The indicators – so called ‘biomarkers’ – are found in the blood.

He said: ‘We hope to find out whether they can reliably distinguish between a healthy person and a person with osteoarthritis, identify which patients’ condition will get worse, and whether a particular drug is working or not.’

The Bristol University team has now been handed £300,000 by medical research charity Arthritis Research UK.
They will use the money to investigate if the biomarkers can be used for diagnosis and also to inform doctors if a patient’s condition is likely to worsen over time.

Source: Mail online


Scientists discover new rare genetic brain disorder

brain-map

International teams of researchers using advanced gene sequencing technology have uncovered a single genetic mutation responsible for a rare brain disorder that may have stricken families in Turkey for some 400 years.

The discovery of this genetic disorder, reported in two papers in the journal Cell, demonstrates the growing power of new tools to uncover the causes of diseases that previously stumped doctors.

Besides bringing relief to affected families, who can now go through prenatal genetic testing in order to have children without the disorder, the discovery helps lend insight into more common neurodegenerative disorders, such as ALS, also known as Lou Gehrig’s disease, the researchers said.

The reports come from two independent teams of scientists, one led by researchers at Baylor College of Medicine and the Austrian Academy of Sciences, and the other by Yale University, the University of California, San Diego, and the Academic Medical Center in the Netherlands.

Both focused on families in Eastern Turkey where marriage between close relatives, such as first cousins, is common. Geneticists call these consanguineous marriages.

In this population, the researchers focused specifically on families whose children had unexplained neurological disorders that likely resulted from genetic defects.

Both teams identified a new neurological disorder arising from a single genetic variant called CLP1. Children born with this disorder inherit two defective copies of this gene, which plays a critical role in the health of nerve cells.

Babies with the disorder have small and malformed brains, they develop progressive muscle weakness, they do not speak and they are increasingly prone to seizures.

Dr Ender Karaca, a post-doctoral associate in the department of molecular and human genetics at Baylor, first encountered the disorder in 2006 and 2007 during his residency training as a clinical geneticist in Turkey.

“We followed them for years,” said Karaca, a lead author on one of the papers. Karaca said he and his colleagues performed some basic genetic tests on the families but to no avail.

He presented these cases at a genetics conference in Istanbul in 2010, where he caught the attention of Dr James Lupski, who leads the Center for Mendelian Genomics at Baylor, a joint program with the Johns Hopkins University School of Medicine funded by the National Human Genome Research Institute

The center is focused on finding and recruiting thousands of patients and families with undiagnosed disease likely caused by single-gene defects known as Mendelian disorders.

Lupski recruited Karaca into his program at Baylor, where the team continued to work on identifying more cases. A broad genetic test known as exome sequencing, which looks at all of the protein-making genes representing about 1 percent of the genetic code, eventually identified five families with similar characteristics and the same CLP1 mutation.

Researchers needed confirmation in lab tests that the defect could cause the neurological problems seen in the families. That came at a meeting in Vienna, when Dr Richard Gibbs, director of Baylor’s Human Genome Sequencing Center, presented the gene as part of a list of suspected disease-causing variants.

In the audience was Dr Josef Penninger of the Austrian Academy of Sciences in Vienna, whose lab had been working on a model of this same genetic variant in mice.

Both the mice and the people with the genetic defect shared similar characteristics. Further experiments by the Vienna team showed the mutant copies of the CLP1 gene affected the survival of key cells in the brain stem of the mice.

“We had patients with an interesting phenotype (symptoms) and a novel gene but no evidence from the lab that these mutations are disease-causing. They had a model organism, a mouse, but they didn’t have evidence that it affected people. It was a perfect storm,” said Baylor geneticist Dr Wojciech Wiszniewski, author of another study.

As the Baylor-led researchers were working on the problem, collaborators at the Yale Center for Mendelian Genomics, another of the government-funded Centers for Mendelian Genomics, were sequencing families in Turkey under the direction of Dr Murat Gunel, a professor of genetics and neurobiology at Yale.

Gunel and colleague Dr Joseph Gleeson at University of California, San Diego, have been focusing on understanding the fundamental mechanisms of how the human brain develops.

Gunel had been collecting DNA samples from children affected with neurodevelopmental brain problems. The team did exome sequencing on more than 2,000 samples, and they, too, turned up a disorder linked with the CLP1 gene.

Further investigation of the genetic data suggested that all of the cases they identified among four, unrelated families were linked with a single, spontaneous mutation in the CLP1 gene that occurred 16 generations, or about 400 years ago.

Gunel, who received his medical degree in Istanbul, said the high rates of marriages between closely related people in Turkey and the Middle East lead to these rare disorders as affected children inherit mutations in the same gene from both of their parents. Without such marriages, children are very unlikely to inherit two mutations in the same gene.

The Yale paper credits Lupski at Baylor for sharing some of his unpublished findings. Gibbs said the whole effort is an “good example of communication-driven discovery.”

Source: Reuters


Human skin grown in lab ‘can replace animal testing’

hman skin

Skin grown in the laboratory can replace animals in drug and cosmetics testing, UK scientists say. A team led by King’s College London has grown a layer of human skin from stem cells – the master cells of the body.

Stem cells have been turned into skin before, but the researchers say this is more like real skin as it has a permeable barrier. It offers a cost-effective alternative to testing drugs and cosmetics on animals, they say.

The outermost layer of human skin, known as the epidermis, provides a protective barrier that stops moisture escaping and microbes entering. Scientists have been able to grow epidermis from human skin cells removed by biopsy for several years, but the latest research goes a step further.

The research used reprogrammed skin cells – which offer a way to produce an unlimited supply of the main type of skin cell found in the epidermis. They also grew the skin cells in a low humidity environment, which gave them a barrier similar to that of true skin.

Skin barrier
Lead researcher Dr Dusko Ilic, of King’s College London, told BBC News: “This is a new and suitable model that can be used for testing new drugs and cosmetics and can replace animal models.

“It is cheap, it is easy to scale up and it is reproducible.” He said the same method could be used to test new treatments for skin diseases.

Researcher Dr Theodora Mauro said it would help the study of skin conditions such as ichthyosis – dry, flaky skin – or eczema. “We can use this model to study how the skin barrier develops normally, how the barrier is impaired in different diseases and how we can stimulate its repair and recovery,” she said.

The Humane Society International, which works to protect animals, including those in laboratories, welcomed the research, published in the journal Stem Cell Reports.

Research and toxicology director Troy Seidle said: “This new human skin model is superior scientifically to killing rabbits, pigs, rats or other animals for their skin and hoping that research findings will be applicable to people – which they often aren’t, due to species differences in skin permeability, immunology, and other factors.”

Source: BBC news